Musculoskeletal Drugs
Musculoskeletal Drugs
Musculoskeletal Drugs
diclofenac) retantion
Cholestasis Decreasing GFR
GOR nephritis
Peptic ulcer
Hemorrhage
Who is at risk for GD ulcers
Elderly
History of PU
Higher dosage
Chronic diseases
Anticoagulant therapy
Corticosteroid use
Tobacco and alcohol
Protection
Misoprostol (PGE1 analog)
Proton Pump inhibitors
Glucocorticoids(GC)
GC are widely used for the suppression of
inflammation in chronic inflammatory
diseases such as asthma, RA,
inflammatory bowel disease and
autoimmune diseases.
GC inhibit the expression of multiple
inflammatory genes
Glucocorticoids(GC)
GC increase the syntesis of lipocortin-1,
that has inhibitory effect on phospholipas
A2 and therefore inhibit the production of
lipid mediators as well as inhbit genes
coding for COX-2.
Some commonly used
glucocoticoids
Equivalent oral dose(mg)
Cortisol 20
Prednisolone 5
Methylprednisolone 4
Triamcinolone 4
Dexamethasone 0.75
Dosing (EULAR)
Low dose up to 7.5 mg/d
Medium dose > 7.5 but ≤ 30 mg/d
High dose >30 but ≤ 100 mg/d
Advers Effects
Bone and muscle:
Osteoporosis
Mean first- year loss of bone ranging from
1.5-20% at the dose range ≤ 10 mg/d
prednisolone.
Addition to GC theraphy Ca and vit D or
bisphosphonate should recieve to patient.
Osteonecrosis
Myopathy
Advers Effects
Cardiovascular:
Fluid retention (Hypertension)
Affect lipid profile
Premature atherosclerotic vascular
disease
Cardiac arrythmias
Advers Effects
Dermatologic and appearance
Skin thinning
Ecchymoses
Cushingoid appearance
Hirsutism
Stria
Impair wound healing
Weight gain
Advers Effects
Gastrointestinal Metabolic and
Gastritis endocrine
Ulcers DM
Gastrointestinal HPA insufficiency
bleeding Neuropsychiatric
Infectious diseases Imsomnia
Ophtalmologic Memory impairment
Cataracts Depression
Increased intra-ocular Psychosis
pressure
Injections of steroids
Contraindications
Any localized or generalized infectious
process,
Fracture, the wearing of a joint brace,
Coagulation problems,
No relief after the first injection.
Muscle relaxants
Spasticity-characteristics
Increased tonic stretch reflexes
Increased flexor muscle spasm
Muscle weakness
Clinical conditions of spasticity:
Cerebral palsy, Multiple sclerosis, Stroke
Clinical spasticity:
Reflex arc involvement
Higher center affects descending pathways leading to alpha
motoneurons hyperexcitability
Mechanisms (↓ spasticity)
– Alteration in stretch reflex arc
– Attenuation of excitation-contraction coupling
SPASMOLYTIC DRUGS
(Central effect)
Diazepam
Baclofen
Tizanidine
Dantrolene
Carisoprodol (Soma, Rela)
chlorphenesin (Maolate)
chlorzoxazone (Paraflex)
cyclobenzaprine (Flexeril)
metaxalone (Skelaxin)
methocarbamol (Robaxin)
orphenadrine (Norflex)
Skeletal
There are 2 main categories of skeletal muscle
relaxants: antispastic (such as baclofen or
dantrolene) for conditions such as cerebral palsy
and multiple sclerosis and antispasmodic agents
for musculoskeletal conditions.
The most commonly prescribed antispasmodic
agents are carisoprodol, cyclobenzaprine,
metaxalone, and methocarbamol.
In comparison trials, no single skeletal muscle
relaxant has been proven to be superior to
another
The most widely studied agent is
cyclobenzaprine, with demonstrated efficacy for
various musculoskeletal conditions but with
significant sedation
Tizanidine, which also causes marked sedation,
or cyclobenzaprine may be useful in patients with
insomnia because of severe muscle spasms.
All skeletal muscle relaxants are
associated with adverse effects including
dizziness and drowsiness,